Thousand Oaks braces for Amgen staff cuts
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: East Ventura County should focus on creating a biotech cluster
When the Business Times broke the story that Amgen was cutting roughly 500 support and operations jobs at its sprawling Thousand Oaks campus, there were gasps — and sighs of relief. Gasps because the world’s largest biotechnology company is the economic engine for the Conejo Valley, East Ventura County and, for that matter, a big Read More →
500 Amgen employees to be re-assigned, relocated or laid off
Nearly 500 Amgen employees in Thousand Oaks have been notified that they will be re-assigned, relocated or laid off as part of a restructuring plan. The biotech giant informed employees on March 22 that they will be reassigned to a new Tampa Bay, Fla. facility and research and development offices in Cambridge, Mass. and South Read More →
Amgen gets European approval for biosimilar of Humira
Thousand Oaks-based Amgen has announced that the European Commission has granted marketing authorization for Amgevita, a drug that treats inflammatory diseases, including moderate-to-severe rheumatoid arthritis. The Amgen biosimilar will compete with AbbVie’s blockbuster drug Humira. “The approval of our first biosimilar by the European Commission is a major milestone not just for Amgen as a company, but for the millions Read More →
Thousand Oaks getting first mixed-use residential development
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen declares $1.15 per share dividend
The board of directors for Thousand Oaks biotechnology company Amgen declared a $1.15 per share dividend March 3 for the second quarter of 2017. The dividend will be paid on June 8 to all stockholders of record as of the close of business on May 17. The company has a market cap of $130.1 billion Read More →
Study shows Amgen’s Blincyto a better alternative than chemotherapy
Amgen’s new leukemia drug Blincyto increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. Results from its Phase 3 Tower study revealed that Blincyto almost doubled median overall survival versus chemotherapy among adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic Read More →
